620 related articles for article (PubMed ID: 34518443)
1. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
2. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Sacramento CQ; Fintelman-Rodrigues N; Temerozo JR; Da Silva APD; Dias SDSG; da Silva CDS; Ferreira AC; Mattos M; Pão CRR; de Freitas CS; Soares VC; Hoelz LVB; Fernandes TVA; Branco FSC; Bastos MM; Boechat N; Saraiva FB; Ferreira MA; Jockusch S; Wang X; Tao C; Chien M; Xie W; Patel D; Garzia A; Tuschl T; Russo JJ; Rajoli RKR; Pedrosa CSG; Vitória G; Souza LRQ; Goto-Silva L; Guimarães MZ; Rehen SK; Owen A; Bozza FA; Bou-Habib DC; Ju J; Bozza PT; Souza TML
J Antimicrob Chemother; 2021 Jun; 76(7):1874-1885. PubMed ID: 33880524
[TBL] [Abstract][Full Text] [Related]
3. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
4. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
5. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
[TBL] [Abstract][Full Text] [Related]
6. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
[TBL] [Abstract][Full Text] [Related]
8. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Horváth G; Halász T; Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
10. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hong CM; Liu CJ; Yeh SH; Chen PJ
J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
[TBL] [Abstract][Full Text] [Related]
11. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
Wang X; Sacramento CQ; Jockusch S; Chaves OA; Tao C; Fintelman-Rodrigues N; Chien M; Temerozo JR; Li X; Kumar S; Xie W; Patel DJ; Meyer C; Garzia A; Tuschl T; Bozza PT; Russo JJ; Souza TML; Ju J
Commun Biol; 2022 Feb; 5(1):154. PubMed ID: 35194144
[TBL] [Abstract][Full Text] [Related]
12. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
[TBL] [Abstract][Full Text] [Related]
13. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
[TBL] [Abstract][Full Text] [Related]
14. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
[TBL] [Abstract][Full Text] [Related]
15. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
Pelosi LA; Voss S; Liu M; Gao M; Lemm JA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513
[TBL] [Abstract][Full Text] [Related]
16. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
McPhee F; Hernandez D; Yu F; Ueland J; Monikowski A; Carifa A; Falk P; Wang C; Fridell R; Eley T; Zhou N; Gardiner D
Hepatology; 2013 Sep; 58(3):902-11. PubMed ID: 23504694
[TBL] [Abstract][Full Text] [Related]
17. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
18. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
20. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
